Skip to search formSkip to main contentSkip to account menu
Prognostic value of F-18-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)
View via Publisher
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
View via Publisher
First-in-human study of a novel somatostatin receptor antagonist Ga-68-NODAGA-LM3 for PET imaging in paraganglioma patients
View via Publisher
Pregnancy and delivery after PRRT without sequelae
View via Publisher
Long-term Nephrotoxicity After PRRT: Mythos or Reality?
View via Publisher
Lu-177-PSMA-617 radioligand therapy in mCRPC patients with a single functioning kidney
View via Publisher
Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Grade 3 Neuroendocrine Neoplasms (NEN)
View via Publisher
Effective Trade-off between Response and Toxicity by Using a Combination of Ac-225 and Lu-177 Labelled PSMA-617 for Progressive End-Stage Metastatic Prostate Cancer
View via Publisher
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License